Market Overview

A Preview Of Chemours Q4 Earnings

Share:
Related
Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside
Earnings Scheduled For May 3, 2018

The Chemours (NYSE: CC) announces its next round of earnings Wednesday. Here's Benzinga's advanced look at Chemours' Q4 earnings report.

Earnings and Revenue

Sell-side analysts expect Chemours' EPS to be near 95 cents per share on sales of $1.55 billion.

Chemours EPS in the same period a year ago totaled 8 cents per share. Sales were $1 billion. If the company were to post earnings inline with the consensus estimate when it reports Wednesday, revenue would be up 17.25 percent from the year-ago period.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate 1.03 0.85 0.5 0.27
EPS Actual 1.12 0.87 0.75 0.08

 

Q4 EPS Estimate: 95 cents per share
Q4 Revenues Estimate: $1 billion

Stock Performance

Over the last 52-week period, shares are up 69.71 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Chemours stock is a Neutral. The strength of this rating has risen over the past 90 days.

Posted-In: Earnings News Previews Trading Ideas

 

Related Articles (CC)

View Comments and Join the Discussion!